A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease
Seong Soo An,1,* Sun Ah Park,2,* Eva Bagyinszky,1 Sun Oh Bae,1 Yoon-Jeong Kim,2 Ji Young Im,2 Kyung Won Park,3 Kee Hyung Park,4 Eun-Joo Kim,5 Jee Hyang Jeong,6 Jong Hun Kim,7 Hyun Jeong Han,8 Seong Hye Choi,9 SangYun Kim10 1Department of Bionano Technology, Gachon University, Seongnam-si, 2Departme...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/47ba15ce05c9499a867b79202bfd75b6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:47ba15ce05c9499a867b79202bfd75b6 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Alzheimer’s disease mutation presenilin apolipoprotein-E Geriatrics RC952-954.6 |
| spellingShingle |
Alzheimer’s disease mutation presenilin apolipoprotein-E Geriatrics RC952-954.6 An SS Park SA Bagyinszky E Bae SO Kim Y Im JY Park KW Park KH Kim E Jeong JH Kim JH Han HJ Choi SH Kim SY A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease |
| description |
Seong Soo An,1,* Sun Ah Park,2,* Eva Bagyinszky,1 Sun Oh Bae,1 Yoon-Jeong Kim,2 Ji Young Im,2 Kyung Won Park,3 Kee Hyung Park,4 Eun-Joo Kim,5 Jee Hyang Jeong,6 Jong Hun Kim,7 Hyun Jeong Han,8 Seong Hye Choi,9 SangYun Kim10 1Department of Bionano Technology, Gachon University, Seongnam-si, 2Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon, 3Department of Neurology, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, 4Department of Neurology, Gachon University Gil Medical Center, Incheon, 5Department of Neurology, Pusan National University Hospital, Busan, 6Department of Neurology, Ewha Womans University Mokdong Hospital, Seoul, 7Department of Neurology, Ilsan Hospital, National Health Insurance Corporation, 8Department of Neurology, Myongii Hospital, Goyang, 9Department of Neurology, Inha University School of Medicine, Incheon, 10Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea *These authors contributed equally to this work Abstract: Early-onset Alzheimer’s disease (EOAD) has distinct clinical characteristics in comparison to late-onset Alzheimer’s disease (LOAD). The genetic contribution is suggested to be more potent in EOAD. However, the frequency of causative mutations in EOAD could be variable depending on studies. Moreover, no mutation screening study has been performed yet employing large population in Korea. Previously, we reported that the rate of family history of dementia in EOAD patients was 18.7% in a nationwide hospital-based cohort study, the Clinical Research Center for Dementia of South Korea (CREDOS) study. This rate is much lower than in other countries and is even comparable to the frequency of LOAD patients in our country. To understand the genetic characteristics of EOAD in Korea, we screened the common Alzheimer’s disease (AD) mutations in the consecutive EOAD subjects from the CREDOS study from April 2012 to February 2014. We checked the sequence of APP (exons 16-17), PSEN1 (exons 3-12), and PSEN2 (exons 3-12) genes. We identified different causative or probable pathogenic AD mutations, PSEN1 T116I, PSEN1 L226F, and PSEN2 V214L, employing 24 EOAD subjects with a family history and 80 without a family history of dementia. PSEN1 T116I case demonstrated autosomal dominant trait of inheritance, with at least 11 affected individuals over 2 generations. However, there was no family history of dementia within first-degree relation in PSEN1 L226F and PSEN2 V214L cases. Approximately, 55.7% of the EOAD subjects had APOE ε4 allele, while none of the mutation-carrying subjects had the allele. The frequency of genetic mutation in this study is lower compared to the studies from other countries. The study design that was based on nationwide cohort, which minimizes selection bias, is thought to be one of the contributors to the lower frequency of genetic mutation. However, the possibility of the greater likeliness of earlier onset of sporadic AD in Korea cannot be excluded. We suggest early AD onset and not carrying APOE ε4 allele are more reliable factors for predicting an induced genetic mutation than the presence of the family history in Korean EOAD population. Keywords: Alzheimer’s disease, mutation, presenilin, apolipoprotein-E, sequencing, early onset Alzheimer’s disease, genetics |
| format |
article |
| author |
An SS Park SA Bagyinszky E Bae SO Kim Y Im JY Park KW Park KH Kim E Jeong JH Kim JH Han HJ Choi SH Kim SY |
| author_facet |
An SS Park SA Bagyinszky E Bae SO Kim Y Im JY Park KW Park KH Kim E Jeong JH Kim JH Han HJ Choi SH Kim SY |
| author_sort |
An SS |
| title |
A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease |
| title_short |
A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease |
| title_full |
A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease |
| title_fullStr |
A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease |
| title_full_unstemmed |
A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease |
| title_sort |
genetic screen of the mutations in the korean patients with early-onset alzheimer’s disease |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/47ba15ce05c9499a867b79202bfd75b6 |
| work_keys_str_mv |
AT anss ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT parksa ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT bagyinszkye ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT baeso ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kimy ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT imjy ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT parkkw ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT parkkh ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kime ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT jeongjh ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kimjh ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT hanhj ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT choish ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kimsy ageneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT anss geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT parksa geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT bagyinszkye geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT baeso geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kimy geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT imjy geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT parkkw geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT parkkh geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kime geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT jeongjh geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kimjh geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT hanhj geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT choish geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease AT kimsy geneticscreenofthemutationsinthekoreanpatientswithearlyonsetalzheimerrsquosdisease |
| _version_ |
1718400526840758272 |
| spelling |
oai:doaj.org-article:47ba15ce05c9499a867b79202bfd75b62021-12-02T05:12:34ZA genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease1178-1998https://doaj.org/article/47ba15ce05c9499a867b79202bfd75b62016-12-01T00:00:00Zhttps://www.dovepress.com/a-genetic-screen-of-the-mutations-in-the-korean-patients-with-early-on-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Seong Soo An,1,* Sun Ah Park,2,* Eva Bagyinszky,1 Sun Oh Bae,1 Yoon-Jeong Kim,2 Ji Young Im,2 Kyung Won Park,3 Kee Hyung Park,4 Eun-Joo Kim,5 Jee Hyang Jeong,6 Jong Hun Kim,7 Hyun Jeong Han,8 Seong Hye Choi,9 SangYun Kim10 1Department of Bionano Technology, Gachon University, Seongnam-si, 2Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon, 3Department of Neurology, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, 4Department of Neurology, Gachon University Gil Medical Center, Incheon, 5Department of Neurology, Pusan National University Hospital, Busan, 6Department of Neurology, Ewha Womans University Mokdong Hospital, Seoul, 7Department of Neurology, Ilsan Hospital, National Health Insurance Corporation, 8Department of Neurology, Myongii Hospital, Goyang, 9Department of Neurology, Inha University School of Medicine, Incheon, 10Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea *These authors contributed equally to this work Abstract: Early-onset Alzheimer’s disease (EOAD) has distinct clinical characteristics in comparison to late-onset Alzheimer’s disease (LOAD). The genetic contribution is suggested to be more potent in EOAD. However, the frequency of causative mutations in EOAD could be variable depending on studies. Moreover, no mutation screening study has been performed yet employing large population in Korea. Previously, we reported that the rate of family history of dementia in EOAD patients was 18.7% in a nationwide hospital-based cohort study, the Clinical Research Center for Dementia of South Korea (CREDOS) study. This rate is much lower than in other countries and is even comparable to the frequency of LOAD patients in our country. To understand the genetic characteristics of EOAD in Korea, we screened the common Alzheimer’s disease (AD) mutations in the consecutive EOAD subjects from the CREDOS study from April 2012 to February 2014. We checked the sequence of APP (exons 16-17), PSEN1 (exons 3-12), and PSEN2 (exons 3-12) genes. We identified different causative or probable pathogenic AD mutations, PSEN1 T116I, PSEN1 L226F, and PSEN2 V214L, employing 24 EOAD subjects with a family history and 80 without a family history of dementia. PSEN1 T116I case demonstrated autosomal dominant trait of inheritance, with at least 11 affected individuals over 2 generations. However, there was no family history of dementia within first-degree relation in PSEN1 L226F and PSEN2 V214L cases. Approximately, 55.7% of the EOAD subjects had APOE ε4 allele, while none of the mutation-carrying subjects had the allele. The frequency of genetic mutation in this study is lower compared to the studies from other countries. The study design that was based on nationwide cohort, which minimizes selection bias, is thought to be one of the contributors to the lower frequency of genetic mutation. However, the possibility of the greater likeliness of earlier onset of sporadic AD in Korea cannot be excluded. We suggest early AD onset and not carrying APOE ε4 allele are more reliable factors for predicting an induced genetic mutation than the presence of the family history in Korean EOAD population. Keywords: Alzheimer’s disease, mutation, presenilin, apolipoprotein-E, sequencing, early onset Alzheimer’s disease, geneticsAn SSPark SABagyinszky EBae SOKim YIm JYPark KWPark KHKim EJeong JHKim JHHan HJChoi SHKim SYDove Medical PressarticleAlzheimer’s diseasemutationpresenilinapolipoprotein-EGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 1817-1822 (2016) |